Oxidative stress in early stage bipolar disorder and the association with response to lithium

Journal of Psychiatric Research

Volumn 50, Issue 1, 2014, Pages 36-41

  de Sousa, Rafael T ^a   Zarate, Carlos A ^b   Zanetti, Marcus V ^a   Costa, Alana C ^a   Talib, Leda L ^a   Gattaz, Wagner F ^a   Machado Vieira, Rodrigo ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Bipolar Disorder; Depression; Lithium; Neuroprotection; Oxidative stress

Indexed keywords

BIOLOGICAL MARKER; CATALASE; GLUTATHIONE PEROXIDASE; LITHIUM CARBONATE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BIPOLAR DEPRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; LIPID PEROXIDATION; MALE; MONOTHERAPY; OXIDATIVE STRESS; PRIORITY JOURNAL; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; TREATMENT DURATION; TREATMENT RESPONSE; YOUNG ADULT; YOUNG MANIA RATING SCALE;

BIPOLAR DISORDER; DEPRESSION; LITHIUM; NEUROPROTECTION; OXIDATIVE STRESS;

ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; CATALASE; DEPRESSION; FEMALE; GLUTATHIONE PEROXIDASE; HUMANS; LITHIUM CARBONATE; MALE; OXIDATIVE STRESS; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892528590     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.11.011     Document Type: Article

References (66)

1. Abdalla D.S., Monteiro H.P., Oliveira J.A., Bechara E.J. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clin Chem 1986, 32:805-807.
2. Andrades M., Ritter C., Moreira J.C., Dal-Pizzol F. Oxidative parameters differences during non-lethal and lethal sepsis development. JSurg Res 2005, 125:68-72.
3. Andreazza A.C., Cassini C., Rosa A.R., Leite M.C., de Almeida L.M., Nardin P., et al. Serum S100B and antioxidant enzymes in bipolar patients. JPsychiatr Res 2007, 41:523-529.
4. Andreazza A.C., Frey B.N., Erdtmann B., Salvador M., Rombaldi F., Santin A., et al. DNA damage in bipolar disorder. Psychiatry Res 2007, 153:27-32.
5. Andreazza A.C., Kapczinski F., Kauer-Sant'Anna M., Walz J.C., Bond D.J., Gonçalves C.A., et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. JPsychiatry Neurosci 2009, 34:263-271.
6. Andreazza A.C., Kauer-Sant'anna M., Frey B.N., Bond D.J., Kapczinski F., Young L.T., et al. Oxidative stress markers in bipolar disorder: a meta-analysis. JAffect Disord 2008, 111:135-144.
7. Andreazza A.C., Shao L., Wang J.F., Young L.T. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 2010, 67:360-368.
8. +-ATPase activity and lipid peroxidation in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2012, 37:56-61.
9. Berk M., Berk L., Dodd S., Cotton S., Macneil C., Daglas R., et al. Stage managing bipolar disorder. Bipolar Disord 2013 Jun 20, [Epub ahead of print]. 10.1111/bdi.12099.
10. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011, 35:804-817.
11. Berman S.B., Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. JNeurochem 1999, 73:1127-1137.
12. Bianchi P., Kunduzova O., Masini E., Cambon C., Bani D., Raimondi L., et al. Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury. Circulation 2005, 112:3297-3305.
13. Bilici M., Efe H., Köroǧlu M.A., Uydu H.A., Bekaroǧlu M., Deǧer O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. JAffect Disord 2001, 64:43-51.
14. Brambilla P., Perez J., Barale F., Schettini G., Soares J.C. GABAergic dysfunction in mood disorders. Mol Psychiatry 2003, 8:721-737. 715.
15. Clay H.B., Sillivan S., Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci 2011, 29:311-324.
16. D'Addario C., Dell'Osso B., Palazzo M.C., Benatti B., Lietti L., Cattaneo E., et al. Selective DNA methylation of BDNF promoter in bipolar disorder: differences among patients with BDI and BDII. Neuropsychopharmacol 2012, 37:1647-1655.
17. de Sousa R.T., van de Bilt M.T., Diniz B.S., Ladeira R.B., Portela L.V., Souza D.O., et al. Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett 2011, 494:54-56.
18. Emdadul Haque M., Asanuma M., Higashi Y., Miyazaki I., Tanaka K., Ogawa N. Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim Biophys Acta 2003, 1619:39-52.
19. Esposito L.A., Melov S., Panov A., Cottrell B.A., Wallace D.C. Mitochondrial disease in mouse results in increased oxidative stress. Proc Natl Acad Sci U S A 1999, 96:4820-4825.
20. First M., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV axis I disorders 1995, Biometrics Research Department, New York Psychiatric Institute, New York. Patient ed.
21. Fontoura P.C., Pinto V.L., Matsuura C., Resende A.e.C., de Bem G.F., Ferraz M.R., et al. Defective nitric oxide-cyclic guanosine monophosphate signaling in patients with bipolar disorder: a potential role for platelet dysfunction. Psychosom Med 2012, 74:873-877.
22. Fountoulakis K.N., Kelsoe J.R., Akiskal H. Receptor targets for antidepressant therapy in bipolar disorder: an overview. JAffect Disord 2012, 138:222-238.
23. Ghribi O., Herman M.M., Spaulding N.K., Savory J. Lithium inhibits aluminum-induced apoptosis in rabbit hippocampus, by preventing cytochrome c translocation, Bcl-2 decrease, Bax elevation and caspase-3 activation. JNeurochem 2002, 82:137-145.
24. Grintzalis K., Zisimopoulos D., Grune T., Weber D., Georgiou C.D. Method for the simultaneous determination of free/protein malondialdehyde and lipid/protein hydroperoxides. Free Radic Biol Med 2013, 59:27-35.
25. Gsell W., Conrad R., Hickethier M., Sofic E., Frölich L., Wichart I., et al. Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. JNeurochem 1995, 64:1216-1223.
26. HAMILTON M. Arating scale for depression. JNeurol Neurosurg Psychiatry 1960, 23:56-62.
27. Haeberle A., Greil W., Russmann S., Grohmann R. Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP. BMC Psychiatry 2012 Sep 21, 12:153.
28. Hastings T.G., Lewis D.A., Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci U S A 1996, 93:1956-1961.
29. Huang C.C., Chang Y.H., Lee S.Y., Chen S.L., Chen S.H., Chu C.H., et al. The interaction between BDNF and DRD2 in bipolar II disorder but not in bipolar I disorder. Am J Med Genet B Neuropsychiatr Genet 2012, 159B:501-507.
30. Khairova R., Pawar R., Salvadore G., Juruena M.F., de Sousa R.T., Soeiro-de-Souza M.G., et al. Effects of lithium on oxidative stress parameters in healthy subjects. Mol Med Rep 2012, 5:680-682.
31. Kim H.K., Andreazza A.C. The relationship between oxidative stress and post-translational modification of the dopamine transporter in bipolar disorder. Expert Rev Neurother 2012, 12:849-859.
32. Konradi C., Eaton M., MacDonald M.L., Walsh J., Benes F.M., Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 2004, 61:300-308.
33. Kuhn D.M., Arthur R.E., Thomas D.M., Elferink L.A. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. JNeurochem 1999, 73:1309-1317.
34. Kuloglu M., Ustundag B., Atmaca M., Canatan H., Tezcan A.E., Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002, 20:171-175.
35. Lai C.T., Yu P.H. Dopamine- and L-beta-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors. Biochem Pharmacol 1997, 53:363-372.
36. Liochev S.I., Fridovich I. The relative importance of HO* and ONOO- in mediating the toxicity of O*-. Free Radic Biol Med 1999, 26:777-778.
37. Lovell M.A., Xie C., Markesbery W.R. Acrolein, a product of lipid peroxidation, inhibits glucose and glutamate uptake in primary neuronal cultures. Free Radic Biol Med 2000, 29:714-720.
38. Machado-Vieira R., Andreazza A.C., Viale C.I., Zanatto V., Cereser V., da Silva Vargas R., et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007, 421:33-36.
39. Machado-Vieira R., Manji H.K., Zarate C.A. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord 2009, 11(Suppl.2):92-109.
40. Machado-Vieira R., Soeiro-De-Souza M.G., Richards E.M., Teixeira A.L., Zarate C.A. Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach. World J Biol Psychiatry 2013 Sep 2.
41. Mahadik S.P., Evans D., Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25:463-493.
42. Manji H., Kato T., Di Prospero N.A., Ness S., Beal M.F., Krams M., et al. Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci 2012, 13:293-307.
43. Miyazaki I., Asanuma M. Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Acta Med Okayama 2008, 62:141-150.
44. Montero D., Walther G., Perez-Martin A., Roche E., Vinet A. Endothelial dysfunction, inflammation, and oxidative stress in obese children and adolescents: markers and effect of lifestyle intervention. Obes Rev 2012, 13:441-455.
45. Nocito A., Dahm F., Jochum W., Jang J.H., Georgiev P., Bader M., et al. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. Gastroenterol 2007, 133:608-618.
46. Nonaka S., Hough C.J., Chuang D.M. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci U S A 1998, 95:2642-2647.
47. +-independent and -dependent bindings of L-[3H]glutamate in rat brain. Life Sci 1986, 39:2411-2418.
48. Ozaki N., Chuang D.M. Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. JNeurochem 1997, 69:2336-2344.
49. Ozcan M.E., Gulec M., Ozerol E., Polat R., Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004, 19:89-95.
50. Palmeira C.M., Santos M.S., Carvalho A.P., Oliveira C.R. Membrane lipid peroxidation induces changes in gamma-[3H]aminobutyric acid transport and calcium uptake by synaptosomes. Brain Res 1993, 609:117-123.
51. Plein H., Berk M. The platelet as a peripheral marker in psychiatric illness. Hum Psychopharmacol 2001, 16:229-236.
52. Polidori M.C., Frei B., Cherubini A., Nelles G., Rordorf G., Keaney J.F., et al. Increased plasma levels of lipid hydroperoxides in patients with ischemic stroke. Free Radic Biol Med 1998, 25:561-567.
53. Raffa M., Barhoumi S., Atig F., Fendri C., Kerkeni A., Mechri A. Reduced antioxidant defense systems in schizophrenia and bipolar I disorder. Prog Neuropsychopharmacol Biol Psychiatry 2012, 39:371-375.
54. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003, 121:109-122.
55. Reddy R., Sahebarao M.P., Mukherjee S., Murthy J.N. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatry 1991, 30:409-412.
56. Schäfer M., Goodenough S., Moosmann B., Behl C. Inhibition of glycogen synthase kinase 3 beta is involved in the resistance to oxidative stress in neuronal HT22 cells. Brain Res 2004, 1005:84-89.
57. Shao L., Young L.T., Wang J.F. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry 2005, 58:879-884.
58. Soeiro-de-Souza M.G., Andreazza A.C., Carvalho A.F., Machado-Vieira R., Young L.T., Moreno R.A. Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder. Int J Neuropsychopharmacol 2013, 16:1505-1512.
59. Stork C., Renshaw P.F. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 2005, 10:900-919.
60. Sun X., Wang J.F., Tseng M., Young L.T. Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. JPsychiatry Neurosci 2006, 31:189-196.
61. Varga V., Jenei Z., Janáky R., Saransaari P., Oja S.S. Glutathione is an endogenous ligand of rat brain N-methyl-D-aspartate (NMDA) and 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors. Neurochem Res 1997, 22:1165-1171.
62. Volterra A., Trotti D., Racagni G. Glutamate uptake is inhibited by arachidonic acid and oxygen radicals via two distinct and additive mechanisms. Mol Pharmacol 1994, 46:986-992.
63. Wasserman M.J., Corson T.W., Sibony D., Cooke R.G., Parikh S.V., Pennefather P.S., et al. Chronic lithium treatment attenuates intracellular calcium mobilization. Neuropsychopharmacol 2004, 29:759-769.
64. Yatham L.N., Kennedy S.H., Parikh S.V., Schaffer A., Beaulieu S., Alda M., et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients withbipolar disorder: update 2013. Bipolar Disord 2013 Feb, 15(1):1-44.
65. Yazlovitskaya E.M., Edwards E., Thotala D., Fu A., Osusky K.L., Whetsell W.O., et al. Lithium treatment prevents neurocognitive deficit resulting from cranial irradiation. Cancer Res 2006, 66:11179-11186.
66. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. Arating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429-435.